ATM-AVI + BAT
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gram-negative Bacterial Infections
Conditions
Gram-negative Bacterial Infections
Trial Timeline
Apr 18, 2023 → Aug 17, 2026
NCT ID
NCT05639647About ATM-AVI + BAT
ATM-AVI + BAT is a phase 2 stage product being developed by Pfizer for Gram-negative Bacterial Infections. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05639647. Target conditions include Gram-negative Bacterial Infections.
What happened to similar drugs?
0 of 2 similar drugs in Gram-negative Bacterial Infections were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05639647 | Phase 2 | Recruiting |
Competing Products
14 competing products in Gram-negative Bacterial Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Cefiderocol + Standard of Care | Shionogi | Phase 2 | 35 |
| Cefiderocol | Shionogi | Pre-clinical | 26 |
| Cefiderocol + Standard of Care | Shionogi | Phase 2 | 35 |
| Cefiderocol + Standard of Care | Shionogi | Phase 2 | 35 |
| HRS-8427 | Jiangsu Hengrui Medicine | Phase 1 | 29 |
| Part A: ATM-AVI Single Dose, Cohorts 1-4 + Part B: Multiple-dose ATM-AVI, Cohorts 1-4 | AbbVie | Phase 2 | 42 |
| IMI/REL + Active Control + Oral Switch | Merck | Phase 2/3 | 38 |
| IMI/REL FDC | Merck | Phase 1 | 29 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Phase 3 | 32 |
| Ceftolozane/Tazobactam 1000/500 mg + Ceftolozane/Tazobactam 30/15 mg/kg + Ceftolozane/Tazobactam 20/10 mg/kg + Ceftolozane/Tazobactam 18/9 mg/kg + Ceftolozane/Tazobactam 12/6 mg/kg | Merck | Phase 1 | 29 |
| nacubactam + meropenem | Roche | Phase 1 | 29 |
| Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3 + Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3 | Pfizer | Phase 2 | 27 |
| tigecycline | Pfizer | Phase 3 | 40 |
| AN3365 + Placebo | Pfizer | Phase 1 | 29 |